Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00328458 · ClinicalTrials.gov registry record · Phase 1
EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT00328458 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 39 participants.
The verdict
NCT00328458, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of the drug EPO906 that could shrink tumors when used with radiation therapy in cancer patients.
Interventions
- DRUG EPO906 (epothilone B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2004-02 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00328458
The ClinicalTrials.gov registry entry for NCT00328458 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EPO906 (epothilone B) is the first listed.
NCT00328458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00328458 about?
NCT00328458 is a clinical study titled "EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients". The purpose of this study is to determine the safety of the drug EPO906 that could shrink tumors when used with radiation therapy in cancer patients.
What is the current status of trial NCT00328458?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2004-02. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00328458?
The interventions under investigation include: EPO906 (epothilone B) (DRUG).
Who is sponsoring clinical trial NCT00328458?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.